Ahren Innovation Capital
Investment Professional (Associate/Senior Associate)
Start Date: Flexible
Role: Associate/Senior Associate Duration: Full time
Location: Remote position
The ideal candidate for this position will identify, review and assess new investment opportunities across Ahren’s four domains: Planet & Efficient Energy; Brain & Artificial Intelligence; Genetics & Platform Technologies; and Space, Robotics & Physics.
To Apply: Please contact Patrick Donnelly (patrick@ahren.co.uk) with a cover letter and one page CV. If you have not worked in early-stage investing before, please send us two investment opportunities within Ahren’s investment domains you would invest in and why. Similarly, contact with questions.
Responsibilities
- Conducting in-depth technology and market research to support the creation of investment theses across one or several Ahren domains
- Sourcing, reviewing, and assessing new investment opportunities for Ahren and being a key point of contact with entrepreneurs
- Performing technical, market, business, and financial due diligence on transactions and supporting the investment process from sourcing to deal completion
- Management and tracking of Ahren portfolio company performance and supporting ad-hoc projects to support portfolio company executives
- Building a network of deep tech academics, entrepreneurs, and investors and leveraging that network for the benefit of Ahren and its portfolio
- Supporting the execution of key internal initiatives including but not limited to quarterly portfolio reviews, investor communications, fund administration, and strategic projects
- Upholding our values and sharing our vision
Minimum Qualifications
- Degree in science, technology, engineering, mathematics, or related technical field
- Relevant investment, or similar financial, experience
- A keen interest in deep science and deep technology that you can talk about, and desire to
- change the world for the better
- Highly commercial and a passion for early-stage technology and entrepreneurship
- Hustle, and the ability to access entrepreneurs and companies that excite you
About us
Ahren is a deep tech and deep science investment firm set up by Alice Newcombe-Ellis alongside co- founding Science Partners (below) that have founded companies and/or technologies that are today valued in excess of $100BN combined.
Ahren’s strategy has an overarching theme: to invest at the intersection of deep tech and deep science in opportunities that are transformational and highly commercial. That intersection is an operative word: we believe wholeheartedly that the future will be cross-domain.
Ahren has >$800M of capital commitments and invests globally between Pre-Seed and Pre-IPO, including the ability to set things up from scratch. Our team members are based in Cambridge and London, UK. Ahren’s portfolio includes AI21 Labs, Graphcore, Zapata Computing, ZOE, Phaidra, Heirloom Carbon, Bicycle Therapeutics, New Culture, and Cellarity, among others.
Ahren’s Founding and Science Partners:
- Alice Newcombe-Ellis (Founding & General Partner), formerly an investor at TPG Capital
- and Lansdowne Partners; Double First-Class degree in Mathematics and Master’s in Maths & Physics from the University of Cambridge; Fulbright and Baker Scholar at Harvard Business School.
- Professor Zoubin Ghahramani, co-founder of Geometric Intelligence (sold to Uber); former Uber Chief Scientist & VP for AI; now Distinguished Scientist and Snr. Research Director at Google Brain.
- Professor Roberto Cipolla, Professor of Information Engineering, Cambridge University; Director of Toshiba’s Cambridge Research Laboratory; Distinguished Fellow of The British Machine Vision Association.
- Professor John Daugman, Professor of Computer Vision and Pattern Recognition at University of Cambridge; inventor of IRIS (eye) recognition technology being used to register India’s 1.4BN citizens and build c.$3BN market.
- Professor Andy Parker, CERN leader (founder of the ATLAS experiment for the Large Hadron Collider); Head of the Cavendish Laboratory (Physics Department), Cambridge University.
- Lord Martin Rees, world-renowned astrophysicist; Astronomer Royal; founder of CSER; former President of the Royal Society and former Master of Trinity College, University of Cambridge.
- Sir Shankar Balasubramanian, principal inventor of the leading next generation human genome sequencing technology core to all sequencing platforms of Illumina (approximately $60BN market cap).
- Professor Steve Jackson, Head of Cancer Research UK Laboratories at the Gurdon Institute, University of Cambridge; originator of Olaparib/Lynparza, now partnered by AstraZeneca with Merck and valued up to $17BN in 2017.
- Sir Venki Ramakrishnan, 2009 Nobel laureate for atomic structure and function of the ribosome; former President of the Royal Society, the UK’s premier science body.
- Sir Gregory Winter, 2018 Nobel laureate for phage display; inventor of technology leading to Humira ($20.7BN sales in 2021, the world’s greatest grossing drug) and founder of three companies. Former Master of Trinity College, University of Cambridge.